Cargando…
Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide
PDE9A is a cGMP-specific phosphodiesterase expressed in neurons throughout the brain that has attracted attention as a therapeutic target to treat cognitive disorders. Indeed, PDE9A inhibitors are under evaluation in clinical trials as a treatment for Alzheimer’s disease and schizophrenia. However,...
Autores principales: | Harms, John F., Menniti, Frank S., Schmidt, Christopher J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716477/ https://www.ncbi.nlm.nih.gov/pubmed/31507355 http://dx.doi.org/10.3389/fnins.2019.00837 |
Ejemplares similares
-
Phosphodiesterase 9A Controls Nitric-oxide Independent cGMP and Hypertrophic Heart Disease
por: Lee, Dong I., et al.
Publicado: (2015) -
cGMP-independent nitric oxide signaling and regulation of the cell cycle
por: Cui, Xiaolin, et al.
Publicado: (2005) -
cGMP Signaling, Phosphodiesterases and Major Depressive Disorder
por: Reierson, Gillian W, et al.
Publicado: (2011) -
Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases
por: Kopra, Kari, et al.
Publicado: (2020) -
Transient kinetics of a cGMP-dependent cGMP-specific phosphodiesterase from Dictyostelium discoideum
Publicado: (1984)